Can-Fite Biopharma Ltd ADR (CANF)

$1.04 -0.01 (-1.00%)
Market Cap 3.74M
Revenue (ttm) 670,000.00
Net Income (ttm) -7.88M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -1,176.12%
Debt to Equity Ratio 0.00
Volume 26,328
Avg Vol 244,254
Day's Range N/A - N/A
Shares Out 3.54M
Stochastic %K 23%
Beta 1.12
Analysts Strong Sell
Price Target $10.83

Company Profile

Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction in Israel. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis. It develops Namodenoson that is in Phase III clinical trial for the treatment of liver cancer; and Phase IIa for the treatment of pancreatic c...

Industry: Biotechnology
Sector: Healthcare
Phone: 972 3 924 1114
Fax: 972 3 924 9378
Address:
26 Ben Gurion Street, Ramat Gan, Israel
DipBuyInvester
DipBuyInvester Jun. 23 at 2:55 AM
$CANF Going to be huge!! Have patience.
0 · Reply
DipBuyInvester
DipBuyInvester Jun. 20 at 10:19 AM
$CANF Potential squeeze ahead!!
0 · Reply
DipBuyInvester
DipBuyInvester Jun. 18 at 3:14 PM
$CANF catch the dip!!
0 · Reply
DipBuyInvester
DipBuyInvester Jun. 17 at 6:08 PM
$CANF No matter what, it’s 10X play. Stay strong.
0 · Reply
Jo_TylerLink
Jo_TylerLink Jun. 17 at 4:26 PM
$CANF
0 · Reply
DipBuyInvester
DipBuyInvester Jun. 16 at 9:50 PM
$CANF https://finance.yahoo.com/news/fite-present-phase-iia-pancreatic-130000499.html
0 · Reply
Sanjaynaik2011
Sanjaynaik2011 Jun. 16 at 5:19 PM
$CANF Crash is coming. This may fall down below $1 mark. This
0 · Reply
Sanjaynaik2011
Sanjaynaik2011 Jun. 16 at 5:19 PM
$CANF This will end up below $1. This always has been case with biotech stocks. Any kind if positive report and it crashes
0 · Reply
DipBuyInvester
DipBuyInvester Jun. 16 at 4:55 PM
$CANF All day in loading zone!! Moon is not that far!!
0 · Reply
Sanjaynaik2011
Sanjaynaik2011 Jun. 16 at 4:15 PM
$CANF When does EVER secret alerts community talk about one single stock and it runs??? It only crashes 50% to 80%. $SHOT, $EKSO, etc ... They might just getting paid for some lousy report like always in my opinion!!!
1 · Reply
Latest News on CANF
Following FDA Compassionate Use Approval for Pancreatic Carcinoma with Can-Fite's Namodenoson, Leading U.S. Medical Centers Seek Authorization for their Patients

Apr 17, 2025, 8:55 AM EDT - 2 months ago

Following FDA Compassionate Use Approval for Pancreatic Carcinoma with Can-Fite's Namodenoson, Leading U.S. Medical Centers Seek Authorization for their Patients

Can-Fite Announces $3.0 Million Registered Direct Offering of American Depositary Shares

Apr 14, 2025, 2:28 PM EDT - 2 months ago

Can-Fite Announces $3.0 Million Registered Direct Offering of American Depositary Shares

Can-Fite Partner Vetbiolix Accelerate Piclidenoson Development with Advanced Clinical Trial for Canine Osteoarthritis in a $3.8 Billion Market

Mar 20, 2025, 9:45 AM EDT - 3 months ago

Can-Fite Partner Vetbiolix Accelerate Piclidenoson Development with Advanced Clinical Trial for Canine Osteoarthritis in a $3.8 Billion Market

Can-Fite to Initiate Phase II Study in the Rare Genetic Disease Lowe Syndrome with Piclidenoson

Mar 19, 2025, 9:00 AM EDT - 3 months ago

Can-Fite to Initiate Phase II Study in the Rare Genetic Disease Lowe Syndrome with Piclidenoson

Can-Fite Innovative Publication: Namodenoson in Liver Cancer Treatment Alongside with Cardiac, Liver, and Neurological Benefits

Mar 3, 2025, 6:00 AM EST - 4 months ago

Can-Fite Innovative Publication: Namodenoson in Liver Cancer Treatment Alongside with Cardiac, Liver, and Neurological Benefits

Join Can-Fite's Exclusive Live Investor Webinar and Q&A Session on February 25

Feb 10, 2025, 7:10 AM EST - 4 months ago

Join Can-Fite's Exclusive Live Investor Webinar and Q&A Session on February 25

Can-Fite BioPharma to Present the Namodenoson Anti-Obesity Effect at BIO CEO & Investor Conference 2025

Feb 5, 2025, 7:00 AM EST - 4 months ago

Can-Fite BioPharma to Present the Namodenoson Anti-Obesity Effect at BIO CEO & Investor Conference 2025

Recognition of the American Society of Clinical Oncology (ASCO) of the Liver Protective Effect of Can-Fite's anti-Cancer Drug Namodenoson

Dec 30, 2024, 7:00 AM EST - 6 months ago

Recognition of the American Society of Clinical Oncology (ASCO) of the Liver Protective Effect of Can-Fite's anti-Cancer Drug Namodenoson

60 Degrees Pharmaceuticals and Can-Fite BioPharma Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

Nov 22, 2024, 9:00 AM EST - 7 months ago

60 Degrees Pharmaceuticals and Can-Fite BioPharma Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

SXTP

Can-Fite Achieves Milestone with First Patient Dosing in Pancreatic Cancer Phase IIa Clinical Trial

Nov 11, 2024, 7:00 AM EST - 8 months ago

Can-Fite Achieves Milestone with First Patient Dosing in Pancreatic Cancer Phase IIa Clinical Trial

Can-Fite anti-Obesity Drug Namodenoson Received Patent Allowance in Australia

Nov 4, 2024, 7:08 AM EST - 8 months ago

Can-Fite anti-Obesity Drug Namodenoson Received Patent Allowance in Australia

Significant Positive Results from Osteoarthritis Clinical Study in Dogs Treated with Piclidenoson

Oct 18, 2024, 9:06 AM EDT - 8 months ago

Significant Positive Results from Osteoarthritis Clinical Study in Dogs Treated with Piclidenoson

FDA Grants Orphan Drug Designation to Can-Fite's Namodenoson for Pancreatic Cancer

Oct 9, 2024, 7:00 AM EDT - 9 months ago

FDA Grants Orphan Drug Designation to Can-Fite's Namodenoson for Pancreatic Cancer

Can-Fite: Pancreatic Carcinoma Phase IIa Clinical Study with Namodenoson Received Regulatory Authorization from the Israeli Ministry of Health

Sep 16, 2024, 7:00 AM EDT - 10 months ago

Can-Fite: Pancreatic Carcinoma Phase IIa Clinical Study with Namodenoson Received Regulatory Authorization from the Israeli Ministry of Health

Can-Fite Reports First Half 2024 Financial Results & Progress in Two Pivotal Phase III Clinical Studies

Aug 29, 2024, 8:15 AM EDT - 10 months ago

Can-Fite Reports First Half 2024 Financial Results & Progress in Two Pivotal Phase III Clinical Studies

OS Therapies and Can-Fite BioPharma Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

Aug 9, 2024, 9:00 AM EDT - 11 months ago

OS Therapies and Can-Fite BioPharma Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

OSTX

Can-Fite Announces Exercise of Warrants for Approximately $5.0 Million in Gross Proceeds

Aug 8, 2024, 7:01 PM EDT - 11 months ago

Can-Fite Announces Exercise of Warrants for Approximately $5.0 Million in Gross Proceeds

Can-Fite Provides Namodenoson Patent Update

Jul 29, 2024, 7:00 AM EDT - 11 months ago

Can-Fite Provides Namodenoson Patent Update

Join Can-Fite's Exclusive Live Investor Webinar and Q&A Session on August 8

Jul 17, 2024, 7:00 AM EDT - 1 year ago

Join Can-Fite's Exclusive Live Investor Webinar and Q&A Session on August 8

Can-Fite Applies for FDA Orphan Drug Designation for Namodenoson in the Treatment of Pancreatic Cancer

Jul 11, 2024, 7:00 AM EDT - 1 year ago

Can-Fite Applies for FDA Orphan Drug Designation for Namodenoson in the Treatment of Pancreatic Cancer

Positive Results from Osteoarthritis Clinical Study in Dogs Reported by Can-Fite's Partner Vetbiolix

Jun 28, 2024, 7:00 AM EDT - 1 year ago

Positive Results from Osteoarthritis Clinical Study in Dogs Reported by Can-Fite's Partner Vetbiolix

Can-Fite: Breakthrough Findings Demonstrate Namodenoson Anti-cancer and Protective Effect Mechanism in the Liver

Jun 24, 2024, 7:00 AM EDT - 1 year ago

Can-Fite: Breakthrough Findings Demonstrate Namodenoson Anti-cancer and Protective Effect Mechanism in the Liver

Can-Fite Received IRB Approval for the Treatment of Pancreatic Cancer with Namodenoson in a Phase IIa Study

Jun 10, 2024, 7:00 AM EDT - 1 year ago

Can-Fite Received IRB Approval for the Treatment of Pancreatic Cancer with Namodenoson in a Phase IIa Study

Can-Fite Updates on its Advanced Liver Cancer Pivotal Phase 3 Study

Jun 5, 2024, 7:00 AM EDT - 1 year ago

Can-Fite Updates on its Advanced Liver Cancer Pivotal Phase 3 Study

Independent Scientists Published a Review Article Demonstrating That Can-Fite Drugs Have Therapeutic Effects on Heart Diseases

May 29, 2024, 7:00 AM EDT - 1 year ago

Independent Scientists Published a Review Article Demonstrating That Can-Fite Drugs Have Therapeutic Effects on Heart Diseases

Can-Fite to Participate in Partnering Meetings at Bio International Convention 2024

May 27, 2024, 7:00 AM EDT - 1 year ago

Can-Fite to Participate in Partnering Meetings at Bio International Convention 2024

Join Can-Fite's Exclusive Live Investor Webinar and Q&A Session on June 6

May 23, 2024, 7:00 AM EDT - 1 year ago

Join Can-Fite's Exclusive Live Investor Webinar and Q&A Session on June 6

Can-Fite: 75 Oncologists and Coordinators from Europe US and Israel Participated in a Conference Aimed at Accelerating Patient Enrolment for the Pivotal Phase 3 Advanced Liver Cancer Study

May 13, 2024, 7:00 AM EDT - 1 year ago

Can-Fite: 75 Oncologists and Coordinators from Europe US and Israel Participated in a Conference Aimed at Accelerating Patient Enrolment for the Pivotal Phase 3 Advanced Liver Cancer Study

Can-Fite BioPharma and Nutriband Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

May 10, 2024, 9:00 AM EDT - 1 year ago

Can-Fite BioPharma and Nutriband Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

NTRB

Can-Fite: FDA Grants IND Clearance for Namodenoson to Treat MASH Patients in a Phase IIb Study

May 9, 2024, 7:00 AM EDT - 1 year ago

Can-Fite: FDA Grants IND Clearance for Namodenoson to Treat MASH Patients in a Phase IIb Study

Can-Fite Received Notice of Allowance from the European Patent Office for the Treatment of Erectile Dysfunction with CF602

May 6, 2024, 7:00 AM EDT - 1 year ago

Can-Fite Received Notice of Allowance from the European Patent Office for the Treatment of Erectile Dysfunction with CF602

Long-term Complete Response to Can-Fite's Namodenoson in Patient with Advanced Liver Cancer: Article Published in a Leading Scientific Journal

Apr 25, 2024, 7:00 AM EDT - 1 year ago

Long-term Complete Response to Can-Fite's Namodenoson in Patient with Advanced Liver Cancer: Article Published in a Leading Scientific Journal

Can-Fite: Scientific Article Published by KOL Presents Namodenoson as a Promising Drug Candidate to Treat Advanced Liver Cancer and MASH

Apr 15, 2024, 7:00 AM EDT - 1 year ago

Can-Fite: Scientific Article Published by KOL Presents Namodenoson as a Promising Drug Candidate to Treat Advanced Liver Cancer and MASH

Can-Fite: Submits FDA with an IND Application to Conduct Phase IIb Clinical Trial of Namodenoson in MASH Patients

Apr 3, 2024, 7:00 AM EDT - 1 year ago

Can-Fite: Submits FDA with an IND Application to Conduct Phase IIb Clinical Trial of Namodenoson in MASH Patients

Can-Fite BioPharma, Ltd. to Present at the LD Micro Invitational XIV

Apr 1, 2024, 7:00 AM EDT - 1 year ago

Can-Fite BioPharma, Ltd. to Present at the LD Micro Invitational XIV

Can-Fite Reports 2023 Financial Results and Clinical Update

Mar 28, 2024, 7:00 AM EDT - 1 year ago

Can-Fite Reports 2023 Financial Results and Clinical Update

Namodenoson Treatment for Pancreatic and Liver Cancer: Data will be Discussed in Out-licensing and Distribution Partnering Meetings at Bio Europe Conference

Mar 11, 2024, 7:00 AM EDT - 1 year ago

Namodenoson Treatment for Pancreatic and Liver Cancer: Data will be Discussed in Out-licensing and Distribution Partnering Meetings at Bio Europe Conference

Can-Fite Broadens its Strong Intellectual Property (IP) for NASH: Received Patent Allowance in Canada

Feb 28, 2024, 7:00 AM EST - 1 year ago

Can-Fite Broadens its Strong Intellectual Property (IP) for NASH: Received Patent Allowance in Canada

Can-Fite Expands the Out-Licensing Deal with Ewopharma to Include the Pancreatic Cancer Indication

Jan 30, 2024, 7:00 AM EST - 1 year ago

Can-Fite Expands the Out-Licensing Deal with Ewopharma to Include the Pancreatic Cancer Indication

Can-Fite: Top Scientific Journal Published Positive Data from the COMFORT-1 Phase III Psoriasis Study

Jan 29, 2024, 7:00 AM EST - 1 year ago

Can-Fite: Top Scientific Journal Published Positive Data from the COMFORT-1 Phase III Psoriasis Study

The Anti-Obesity Effect of Can-Fite's Namodenoson: Molecular Mechanism of Action in Pre-clinical and Human Studies

Dec 20, 2023, 7:00 AM EST - 1 year ago

The Anti-Obesity Effect of Can-Fite's Namodenoson: Molecular Mechanism of Action in Pre-clinical and Human Studies

Can-Fite's Namodenoson for the Treatment of Pancreatic Cancer Patients: Progress in Clinical Development

Dec 4, 2023, 7:00 AM EST - 1 year ago

Can-Fite's Namodenoson for the Treatment of Pancreatic Cancer Patients: Progress in Clinical Development

Can-Fite Reports Third Quarter 2023 Financial Results and Clinical Update

Nov 30, 2023, 7:00 AM EST - 1 year ago

Can-Fite Reports Third Quarter 2023 Financial Results and Clinical Update

Can-Fite Announces Exercise of Warrants for Approximately $3.0 Million in Gross Proceeds

Nov 21, 2023, 1:53 PM EST - 1 year ago

Can-Fite Announces Exercise of Warrants for Approximately $3.0 Million in Gross Proceeds

Can-Fite: Complete Response and 6.9 Years Overall Survival in a Patient with Advanced Liver Cancer Treated with Namodenoson

Nov 21, 2023, 7:00 AM EST - 1 year ago

Can-Fite: Complete Response and 6.9 Years Overall Survival in a Patient with Advanced Liver Cancer Treated with Namodenoson

Can-Fite Issues Business Update: All Clinical Programs and Business Development Activities Remain Solidly on Track

Nov 1, 2023, 7:00 AM EDT - 1 year ago

Can-Fite Issues Business Update: All Clinical Programs and Business Development Activities Remain Solidly on Track

Can Fite: Namodenoson Inhibits Pancreatic Carcinoma Published in Leading Scientific Journal; Robust anti-Cancer Effect & Molecular Mechanism of Action

Oct 30, 2023, 7:00 AM EDT - 1 year ago

Can Fite: Namodenoson Inhibits Pancreatic Carcinoma Published in Leading Scientific Journal; Robust anti-Cancer Effect & Molecular Mechanism of Action

Can-Fite to Harness Artificial Intelligence to Develop Novel Anti-Cancer Drugs

Oct 26, 2023, 7:00 AM EDT - 1 year ago

Can-Fite to Harness Artificial Intelligence to Develop Novel Anti-Cancer Drugs

Can-Fite to Share its Rare Genetic Disease Lowe Syndrome Novel Treatment with Orphan Drug Japanese Companies

Oct 9, 2023, 7:00 AM EDT - 1 year ago

Can-Fite to Share its Rare Genetic Disease Lowe Syndrome Novel Treatment with Orphan Drug Japanese Companies

Can-Fite Novel Approach for the Treatment of Pancreatic Carcinoma with Namodenoson Receives Appreciation of the American Association of Cancer Research (AACR)

Sep 27, 2023, 7:00 AM EDT - 1 year ago

Can-Fite Novel Approach for the Treatment of Pancreatic Carcinoma with Namodenoson Receives Appreciation of the American Association of Cancer Research (AACR)

DipBuyInvester
DipBuyInvester Jun. 23 at 2:55 AM
$CANF Going to be huge!! Have patience.
0 · Reply
DipBuyInvester
DipBuyInvester Jun. 20 at 10:19 AM
$CANF Potential squeeze ahead!!
0 · Reply
DipBuyInvester
DipBuyInvester Jun. 18 at 3:14 PM
$CANF catch the dip!!
0 · Reply
DipBuyInvester
DipBuyInvester Jun. 17 at 6:08 PM
$CANF No matter what, it’s 10X play. Stay strong.
0 · Reply
Jo_TylerLink
Jo_TylerLink Jun. 17 at 4:26 PM
$CANF
0 · Reply
DipBuyInvester
DipBuyInvester Jun. 16 at 9:50 PM
$CANF https://finance.yahoo.com/news/fite-present-phase-iia-pancreatic-130000499.html
0 · Reply
Sanjaynaik2011
Sanjaynaik2011 Jun. 16 at 5:19 PM
$CANF Crash is coming. This may fall down below $1 mark. This
0 · Reply
Sanjaynaik2011
Sanjaynaik2011 Jun. 16 at 5:19 PM
$CANF This will end up below $1. This always has been case with biotech stocks. Any kind if positive report and it crashes
0 · Reply
DipBuyInvester
DipBuyInvester Jun. 16 at 4:55 PM
$CANF All day in loading zone!! Moon is not that far!!
0 · Reply
Sanjaynaik2011
Sanjaynaik2011 Jun. 16 at 4:15 PM
$CANF When does EVER secret alerts community talk about one single stock and it runs??? It only crashes 50% to 80%. $SHOT, $EKSO, etc ... They might just getting paid for some lousy report like always in my opinion!!!
1 · Reply
Bessa1995
Bessa1995 Jun. 16 at 1:59 PM
$CANF 👀
0 · Reply
DipBuyInvester
DipBuyInvester Jun. 16 at 1:30 PM
$CANF Real time alert. Buy the dip.
0 · Reply
ItTakesItAll
ItTakesItAll Jun. 16 at 1:27 PM
$CANF Adding, looking great! Cash rich, liver and pancreatic cancer drug, FDA compassionate dealings back 04/2025 and about to present ph 2a at BIO today -6/19.
2 · Reply
Surfratt
Surfratt Jun. 16 at 1:03 PM
$CANF
1 · Reply
Sensore
Sensore Jun. 13 at 12:24 PM
$CANF .......
0 · Reply
markos84
markos84 Jun. 9 at 2:27 PM
$CANF will explode before August! BUY BUY BUY
0 · Reply
BioRich
BioRich Jun. 9 at 1:48 PM
$CANF looks like a good day to buy. Cheers!
0 · Reply
Sensore
Sensore Jun. 5 at 6:02 PM
$CANF ..
0 · Reply
Sensore
Sensore Jun. 5 at 1:58 PM
$CANF ..
0 · Reply
markos84
markos84 Jun. 3 at 9:05 PM
$CANF loading more down here
1 · Reply
BioRich
BioRich Jun. 2 at 1:35 PM
$XBI This week's New Bio picks you many not have heard of: $TLSA (Not Tesla, TSLA, Tiziana Life Sciences) $CANF $LPCN $VNDA MIST, CAPR, GUTS, CADL and NRSN are still huge winners but figured I would try something new. So many great opportunities out there. Follow/Subscribe for more suggestions and perspective. Would love to hear yours, too. That's how we find these gems and learn. Let's make some money. Cheers! ~BioRich Capital
2 · Reply
markos84
markos84 May. 27 at 8:19 PM
$CANF This summer Phase-III news will push this over $2 https://ir.canfite.com/news-events/press-releases/detail/1087/can-fite-has-raised-175-million-in-total-to-date-for-the
0 · Reply